Tuesday, February 08, 2011 3:29:07 PM
While the FTC would no doubt disallow TEVA from "cornering the market" on generic versions of enox (and Copaxone?),
I'm not sure on what basis the FTC would object. As of today, because Sandoz has all the licenses for the technology for Enox and I'd assume copax if Momenta has any roll in either drug from a production point of view.
I really don't have a clue what the current roll that Momenta plays in Copax. It probably has little roll in Enox.
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
